Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hollmann

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
Clinical Breast Cancer|May 24, 2022
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast CancerRami S Vanguri, Kathleen M Fenn, Matthew R Kearney, et al.
Cancer Discovery|August 9, 2023
GABA Regulates Electrical Activity and Tumor Initiation in MelanomaMohita Tagore, Emiliano Hergenreder, Sarah C Perlee, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Nature Communications|December 13, 2017
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancerBarbara Oldrini, Wan-Ying Hsieh, Hediye Erdjument-Bromage, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Automated classification of cellular expression in multiplexed imaging data with NimbusJ Lorenz Rumberger, Noah F Greenwald, Jolene S Ranek, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
Clinical Breast Cancer|May 24, 2022
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast CancerRami S Vanguri, Kathleen M Fenn, Matthew R Kearney, et al.
Cancer Discovery|August 9, 2023
GABA Regulates Electrical Activity and Tumor Initiation in MelanomaMohita Tagore, Emiliano Hergenreder, Sarah C Perlee, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Nature Communications|December 13, 2017
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancerBarbara Oldrini, Wan-Ying Hsieh, Hediye Erdjument-Bromage, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analysesClaire F Friedman, Christine Spencer, Christopher R Cabanski, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Automated classification of cellular expression in multiplexed imaging data with NimbusJ Lorenz Rumberger, Noah F Greenwald, Jolene S Ranek, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Pageof 10